SAN DIEGO, Feb. 3, 2021 /PRNewswire/ -- ViaCyte, Inc., a clinical-stage regenerative medicine company, today announced that the first type 1 diabetes (T1D) patients have been implanted in a Phase 2 ...
SAN DIEGO, Feb. 3, 2021 /PRNewswire/ — ViaCyte, Inc., a clinical-stage regenerative medicine company, today announced that the first type 1 diabetes (T1D) patients have been implanted in a Phase 2 ...
SAN DIEGO and NEWARK, Del., March 29, 2017 /PRNewswire/ -- ViaCyte, Inc., a privately-held regenerative medicine company, and W. L. Gore & Associates, Inc. ("Gore"), a global materials science company ...
Vertex Pharmaceuticals said today it has agreed to acquire ViaCyte for $320 million cash, in a deal that bolsters the buyer’s diabetes pipeline with ViaCyte’s triple-pronged attack against the disease ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果